Clinical research
Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis: A Randomized Clinical Trial
Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Kumar RS, Iliayas S, Menon PA, Selvaraju S, Pooranagangadevi NP, Bhavani PK, Ponnuraja C, Dilip M, Ramachandran R. Clinical Infectious Diseases, Spetember 2011
The clinical study aimed at assessing the effect of Nevirapine (NVP) in HIV-infected patients with TB compared to the standard therapy with Efavirenz (EFV). A randomized control clinical trial was carried out, pateints were treated with [2 months of Ethambutol, Isoniazid, Rifampicin, Pyrazinamide / 4 months of Isoniazid and Rifampicin and randomized to receive once-daily EFV at a dose of 600 mg or NVP at a dose of 400 mg. Results showed failure in the NVP arm of the trial, and the study was halted, showing that a regimen with NVP administered daily was inferior to EFV, and was associated with frequent virologic failure and death.
For access to the publication please click here.
